Diagnostics

By bridging diagnostic testing with surgical simulation, Carrot’s latest acquisition signals a high-margin shift in how clinics manage the cataract pipeline.

As UPMC wins a top patient safety award for genomic surveillance, diagnostic startups are leveraging academic ties to prove WGS can deliver a 3.2x ROI.

A newly expanded partnership between ALZpath and Quanterix signals a massive shift in neurology, replacing costly PET scans with scalable blood-based biomarkers.

Oku Digital Health is bringing AI-powered retinal screening to primary care, turning the eye into a window for cardiovascular and systemic health.

Co-Diagnostics brings its point-of-care PCR platform to Johannesburg, betting on emergency outbreak funding to outpace a rapidly shrinking cash runway.

As liver cancer deaths near 31,000 annually, a new House resolution and AI-driven blood tests aim to fix a broken screening system for high-risk patients.

AIRS Medical's FDA-cleared SwiftSight transforms MRI body composition into a sub-five-minute, radiation-free scan, unlocking new revenue for imaging centers.

By automating point-of-care diagnostics, Antech’s new trūRapid Reader aims to capture high-margin consumable sales while curing clinical workflow headaches.

As commercial sperm banks expand genetic testing to include adult-onset cancer risks, prospective parents face a new frontier of complex, life-altering data.

By mandating hereditary cancer testing for all new sperm donors, Xytex is pushing the fertility industry into complex ethical and legal territory.

As 20/20 BioLabs brings its needle-free, AI-powered cancer tests to the Maxim Growth Summit, the startup faces intense scrutiny over its financial runway.

As Eve Wellness opens its second Bay Area clinic, the direct-to-consumer model sparks debate over AI ultrasound, patient autonomy, and false positives.

HoneyNaps is transforming clinical trials by turning its FDA-cleared AI diagnostic software into a specialized Contract Research Organization for sleep data.

As Chinese medtech giant Sinocare unveils its chronic disease portfolio in Milan, the push to decentralize diagnostics from hospitals to pharmacies accelerates.

As precision medicine demands standardized biomarker data, a massive network of independent labs is turning to investment banking to negotiate with Big Pharma.

HCA Healthcare is outsourcing its Charleston breast imaging to Solis Mammography, blending boutique comfort with hospital-grade AI diagnostics.

Armed with $33 million in Series B funding, the microbiome data platform is building a B2B clinical infrastructure to power precision medicine.

A new blood test promises to predict scoliosis progression with perfect accuracy. But do the corporate ties and statistical claims hold up to scrutiny?

With a $22.3 million NIH renewal, Florida's premier Alzheimer's consortium is pioneering non-invasive AI imaging, blending academic rigor with medtech agility.

Fueled by surging Iqirvo royalties and a new Medicare diagnostic code, GENFIT is quietly restructuring its pipeline to dominate intensive care hepatology.